Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
DOI:
https://doi.org/10.24265/horizmed.2025.v25n3.09Keywords:
Medulloblastoma , Immunohistochemistry , Child , NeoplasmsAbstract
Medulloblastomas are the most common malignant brain neoplasms in children. Immunohistochemical
(IHC) markers can determine a molecular classification, using the markers GAB1, YAP1, β-catenin, P53, and Ki67. The classification of these neoplasms into molecular groups has proven to be clinically and therapeutically significant. The clinical outcomes of medulloblastoma include death, adverse
effects or conditions, and tumor recurrence. The objective of this research was to determine the individual association between the IHC markers used for molecular group classification and the clinical outcome in patients with medulloblastoma treated at the Instituto Nacional de Salud del Niño (INSN - National Institute of Child Health) during the period 2013–2022. The population consisted of 58 patients. The individual IHC expression of GAB1, YAP1, β-catenin, p53, and Ki67 in paraffin-embedded biopsies was compared with the clinical outcomes. Descriptive statistics and bivariate analysis were used to determine associations. The desmoplastic/nodular variant was the most commonly observed histological type of medulloblastoma, and there was a high frequency of IHC expression of YAP1 and an association between IHC expression of YAP1 and adverse effects. The clinicopathological characteristics of our cases were similar to those described in China. The finding may be useful as a prognostic marker of adverse effects in pediatric medulloblastoma.
Downloads
References
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D,
et al. The 2021 WHO classification of tumors of the central nervous
system: a summary. Neuro-Oncol [Internet]. 2021;23(8):1231-51.
Disponible en: https://doi.org/10.1093/neuonc/noab106
Instituto Nacional de Enfermedades Neoplásicas. Registro de cáncer de
Lima Metropolitana 2013-2015 [Internet]. Lima: INEN; 2021. Disponible
en: https://portal.inen.sld.pe/wp-content/uploads/2022/01/REGISTRODE-
CANCER-DE-LIMA-METROPOLITANA-2013-2015.pdf
Juraschka K, Taylor MD. Medulloblastoma in the age of molecular
subgroups: a review. J Neurosurg Pediatr [Internet]. 2019;24(4):353-
Disponible en: https://doi.org/10.3171/2019.5.PEDS18381
D’Arcy CE, Nobre LF, Arnaldo A, Ramaswamy V, Taylor MD, Naz-Hazrati L,
et al. Immunohistochemical and nanoString-based subgrouping of
clinical medulloblastoma samples. J Neuropathol Exp Neurol [Internet].
;79(4):437-47. Disponible en: https://doi.org/10.1093/jnen/
nlaa005
Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al.
Medulloblastoma: clinicopathological correlates of SHH, WNT, and
non-SHH/WNT molecular subgroups. Acta Neuropathol [Internet].
;121(3):381-96. Disponible en: https://doi.org/10.1007/s00401-
-0800-8
Louis DN, Perry A, Reinfenberger G, von Deimling A, Figarella-Branger
D, Cavenee WK, et al. The 2016 WHO classification of tumors of the
central nervous system: a summary. Acta Neuropathol [Internet].
;131(6):803-20. Disponible en: https://doi.org/10.1007/s00401-
-1545-1
Tauziède-Espariat A, Huybrechts S, Indersie E, Dufour C, Puget S,
Chivet A, et al. Diagnostic accuracy of a reduced immunohistochemical
panel in medulloblastoma molecular subtyping, correlated to DNAmethylation
analysis. Am J Surg Pathol [Internet]. 2021;45(4):558-66.
Disponible en: https://doi.org/10.1097/PAS.0000000000001640
Bárcenas LP. Clasificación de una serie de meduloblastomas en grupos
genéticamente definidos por medio de un panel de inmunohistoquímica
en pacientes de un hospital pediátrico [tesis de posgrado]. Bogotá:
Universidad Nacional de Colombia; 2021. Disponible en: https://
repositorio.unal.edu.co/handle/unal/78888
Vasquez L, Alvarez C, León E. Childhood medulloblastoma: singlecenter
experience of 16 years in Peru. Pediatr Blood Cancer [Internet].
;64:e26772. Disponible en: https://doi.org/10.1002/pbc.26772
Liu Y, Xiao B, Li S, Liu J. Risk factors for survival in patients with
medulloblastoma: a systematic review and meta-analysis. Front Oncol
[Internet]. 2022;12:827054. Disponible en: https://doi.org/10.3389/
fonc.2022.827054
Dangouloff-Ros V, Varlet P, Levy R, Beccaria K, Puget S, Dufour C,
et al. Imaging features of medulloblastoma: conventional imaging,
diffusion-weighted imaging, perfusion-weighted imaging, and
spectroscopy: from general features to subtypes and characteristics.
Neurochirurgie [Internet]. 2021;67(1):6-13. Disponible en: https://
doi.org/10.1016/j.neuchi.2017.10.003
Shuangshoti S, Tadadontip P, Techavichit P, Thorner PS,
Shuangshoti S, Teerapakpinyo C. Simplified molecular subtyping of
medulloblastoma for reduced cost and improved turnaround time.
Appl Immunohistochem Mol Morphol [Internet]. 2020;28(7):538-43.
Disponible en: https://doi.org/10.1097/PAI.0000000000000794
Jiang T, Zhang Y, Wang J, Du J, Raynald, Qiu X, et al. A retrospective
study of progression-free and overall survival in pediatric
medulloblastoma based on molecular subgroup classification: a
single-institution experience. Front Neurol [Internet]. 2017;8:198.
Disponible en: https://doi.org/10.3389/fneur.2017.00198
Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott
PA. Medulloblastomics revisited: biological and clinical insights from
thousands of patients. Nat Rev Cancer [Internet]. 2020;20(1):42-56.
Disponible en: https://doi.org/10.1038/s41568-019-0223-8
Wu S, Liu Y, Zheng Y, Dong J, Pan D. The TEAD/TEF family protein
Scalloped mediates transcriptional output of the Hippo growthregulatory
pathway. Dev Cell [Internet]. 2008;14(3):388-98.
Disponible en: https://doi.org/10.1016/j.devcel.2008.01.007
Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J. The TEAD/TEF
family of transcription factor Scalloped mediates Hippo signaling in
organ size control. Dev Cell [Internet]. 2008;14(3):377-87. Disponible
en: https://doi.org/10.1016/j.devcel.2008.01.006
Marx A, Schumann A, Höflmayer D, Bady E, Hube-Magg C, Möller K,
et al. Up regulation of the Hippo signalling effector YAP1 is linked to
early biochemical recurrence in prostate cancers. Sci Rep [Internet].
;10(1):8916. Disponible en: https://doi.org/10.1038/s41598-
-65772-w
Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of
yes-associated protein contributes to progression and poor
prognosis of non-small-cell lung cancer. Cancer Sci [Internet].
;101(5):1279-85. Disponible en: https://doi.org/10.1111/
j.1349-7006.2010.01511.x
Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, et al. Overexpression of
YAP 1 contributes to progressive features and poor prognosis of human
urothelial carcinoma of the bladder. BMC Cancer [Internet]. 2013;13:349.
Disponible en: https://doi.org/10.1186/1471-2407-13-349
Wu Y, Hou Y, Xu P, Deng Y, Liu K, Wang M, et al. The prognostic
value of YAP1 on clinical outcomes in human cancers. Aging (Albany
NY) [Internet]. 2019;15(19):8681-700. Disponible en: https://doi.
org/10.18632/aging.102358
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 1970 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
